Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages

Key Points

• Analyst sentiment is moderately bullish: Six of eight covering firms rate Odyssey Therapeutics a buy, while one recommends holding and one recommends selling. The consensus 12-month price target is $35.75, with recent targets ranging from $29 to $44.
• Odyssey shares opened at $20.73, compared with a 52-week range of $15.10 to $29.05, and the company has a market capitalization of approximately $996 million.
• The biotechnology company reported a quarterly loss of $1.74 per share, and analysts expect a full-year loss of approximately $6.20 per share. Several institutional investors, including Citadel Advisors and State Street, recently initiated positions.

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $35.75.

Several brokerages have recently commented on ODTX. Weiss Ratings began coverage on Odyssey Therapeutics in a report on Tuesday, August 11th. They set a "sell (d+)" rating for the company. JPMorgan Chase & Co. raised their target price on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. HC Wainwright started coverage on shares of Odyssey Therapeutics in a research report on Thursday, August 27th. They set a "buy" rating and a $44.00 target price for the company. Wall Street Zen cut shares of Odyssey Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 20th. Finally, Oppenheimer reissued an "outperform" rating and issued a $40.00 price target on shares of Odyssey Therapeutics in a report on Thursday, June 18th.

Odyssey Therapeutics Price Performance

NASDAQ:ODTX opened at $20.73 on Monday. Odyssey Therapeutics has a 52-week low of $15.10 and a 52-week high of $29.05. The company's fifty day simple moving average is $22.73. The company has a market capitalization of $996.28 million and a price-to-earnings ratio of -3.06.

Odyssey Therapeutics (NASDAQ:ODTX - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. On average, equities analysts predict that Odyssey Therapeutics will post -6.2 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp purchased a new stake in Odyssey Therapeutics during the second quarter valued at about $1,477,000. Citadel Advisors LLC bought a new stake in Odyssey Therapeutics during the second quarter worth about $4,162,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Odyssey Therapeutics in the 2nd quarter worth about $601,000.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for serious diseases, with an emphasis on immunology and oncology. The company uses a combination of human genetics, functional genomics, computational biology, machine learning and medicinal chemistry to identify disease targets and advance potential therapeutic programs.

Odyssey's research and development activities are centered on small-molecule medicines designed to address genetically validated targets and specific disease mechanisms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.